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Abstract  
Introduction: To review the performance of non-invasive prenatal testing (NIPT) for detection of 
trisomy 21, 18 and 13 (T21, T18 and T13) in a general pregnant population as well as to update the 
data on high-risk pregnancies. Material and methods: Systematic Review and Meta-Analysis. 
PubMed, Embase and the Cochrane Library were searched. Methodological quality was rated using 
QUADAS and scientific evidence using GRADE. Summary measures of diagnostic accuracy were 
calculated using a bivariate random-effects model. Results: In a general pregnant population, there 
is moderate evidence that the pooled sensitivity is 0.993 (95% 0.955 to 0.999) and specificity was 
0.999 (95% 0.998 to 0.999) for the analysis of T21. Pooled sensitivity and specificity for T13 and T18 
was not calculated in this population due to the low number of studies. In a high-risk pregnant 
population, there is moderate evidence that the pooled sensitivities for T21 and T18 are 0.998 (95% 
CI 0.981 to 0.999) and 0.977 (95% CI 0.958 to 0.987) respectively, and low evidence that the pooled 
sensitivity for T13 is 0.975 (95% CI 0.819 to 0.997). The pooled specificity for all three trisomies is 
0.999 (95% 0.998 to 0.999). Conclusions: This is the first meta-analysis using GRADE that shows that 
NIPT performs well as a screen for trisomy 21 in a general pregnant population. Although the false 
positive rate is low compared to First Trimester Combined Screening, women should still be advised 
to confirm a positive result by invasive testing if termination of pregnancy is under consideration. 
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Abbreviations 
AUC  area under the curve  
cfDNA  cell-free DNA  
DOR  diagnostic odds ratios 
FN  false negatives  
FP  false positive  
FTS  first trimester combined screening  
LR-  negative likelihood ratio 
LR+ positive likelihood ratio 
MPSS  massive parallel shotgun sequencing  
NIPT  non-invasive prenatal testing  
PICO  P – population, I – index test, C – control/reference test and O – outcome 
SNP  single nucleotide polymorphisms 
SROC  summary receiver operating characteristics 
T13 trisomy 13 
T18  trisomy 18 
T21 trisomy 21 
t-MPS  targeted massive parallel sequencing 
TN  true negatives  
TP  true positives  
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Key message 
Non-invasive prenatal testing performs well as a screen for trisomy 21 in a general pregnant 
population.  
 
Introduction 
Prenatal diagnosis, including screening and diagnosis of chromosome aberrations, has been 
offered in various forms as part of prenatal care during the last 40 years (1). Diagnosis of 
chromosome aberrations requires either first-trimester chorionic villus sampling (CVS) or 
second-trimester amniocentesis. However, these invasive procedures entail a miscarriage risk of 
0.1 – 0.5 % (2, 3).  
The presence of fetal cell-free DNA (cfDNA) in maternal circulation was first demonstrated by Lo 
et al. (4). This finding led to the discovery that cfDNA obtained from maternal plasma could be 
used for fetal aneuploidy analysis, termed non-invasive prenatal testing (NIPT), a long-awaited 
improvement to reduce invasive procedures and accompanying miscarriage risk (5, 6). NIPT for 
fetal aneuploidy analysis was introduced clinically in 2011 and is implemented in many 
countries worldwide; more than 2 million procedures have hitherto been performed (7). Many 
studies have investigated analysis of cfDNA in maternal blood for detection of trisomies 21, 18 
and 13 in women at high risk of aneuploidy, finding weighted pooled detection rates of 99.2% 
for trisomy 21 (T21), 96.3% for trisomy 18 (T18) and 91.0% for trisomy 13 (T13), as well as false 
positive (FP) rates of 0.09% for T21 and 0.13% for T18 and T13 (8). However, significant data 
from large studies on test performance in a general (i.e. average-risk) pregnant population 
have, until recently, been lacking (9, 10). The objective of this meta-analysis was to update the 
data on high-risk pregnancies, including studies published up until April 2015, and, more 
importantly, present data concerning test performance in a general pregnant population at 
average risk of aneuploidy. 
 
Material and methods 
The systematic literature review 
The Cochrane Collaboration definition of a systematic review was applied, i.e. “A systematic 
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review attempts to identify, appraise and synthesize all the empirical evidence that meets pre-
specified eligibility criteria to answer a given research question. Researchers conducting 
systematic reviews use explicit methods aimed at minimizing bias, in order to produce more 
reliable findings that can be used to inform decision making.” (www.thecochranelibrary.com). 
 
Literature search  
The literature search included the databases PubMed, Embase, and the Cochrane Library up until 
April 2, 2015. The MeSH terms used were: ”Down Syndrome”, “Patau Syndrome”, “Trisomy 
18-Like Syndrome”, “Chromosomes, Human, Pair 13”, “Chromosomes, Human, Pair 18”, and 
“Chromosomes, Human, Pair 21”. In addition to MeSH terms, free-text words were used. For the 
search block regarding NIPT, only free- text terms were used, since there was no MeSH term for 
this concept. Detailed information about the search strategy can be found at 
http://www.sbu.se/upload/Publikationer/Content0/3/NIPT/Bilaga%205%20S%C3%B6kstrategier
.pdf 
 
Inclusion and exclusion criteria 
Study selection was based on the following criteria using PICO (P – population, I – index test, C – 
control/reference test and O – outcome) (11). Population 1: Pregnant women at high risk of 
carrying a fetus with chromosome aberration (as determined by study authors, which could 
include women of varying risk level but defined as being at high risk because of different risk 
factors such as e.g. assessed being at high-risk on biochemical screening, first trimester 
combined screening (FTS), abnormal ultrasound scan or maternal age). Population 2: Pregnant 
women at average risk of carrying a fetus with chromosome aberration, i.e. a general pregnant 
population. The index test was NIPT, using cfDNA, of trisomies 13, 18, or 21. Invasive genetic 
testing or phenotype at birth were accepted as reference tests. Outcome measures were 
sensitivity, specificity and number of true positives (TP), FP, true negatives (TN) and false 
negatives (FN). The complementary inclusion criteria were primary study in English or 
Scandinavian language on the analysis of trisomy 13, 18 or 21 in singleton pregnancies, 
published in 1998-2015 in a peer-review journal, with reported, or data enabling calculation of, 
sensitivity and specificity. Exclusion criteria were RNA analysis, absence of primary data, study 
population < 100 women and abstract/letter/review. Formal screening of search results against 
inclusion and exclusion criteria and risk of bias (quality) assessment was performed according to 
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a pre-specified protocol, PROSPERO registration number CRD42015020076, available at 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020076. 
 
Study selection and data extraction 
Two authors (EI, BJ) individually reviewed all abstracts and made separate decisions based on 
inclusion and exclusion criteria. If at least one reviewer was considering an abstract for 
inclusion, the full-text article was reviewed. The reviewers individually decided whether a study 
could be included and contained data suitable for the subsequent analysis of clinical validity, 
and extracted the relevant data from each selected study using a standard form. The review 
form was designed to capture primary data, including study type, number of samples, FN and FP 
results, sensitivity and specificity levels, indeterminate cases, reference test (i.e. method used 
to confirm NIPT results), methodology and whether the study was sponsored by a commercial 
company. Inter-reviewer discrepancies were resolved by discussion. Where one of the review 
authors was co-author of a selected study, MHA and JD replaced that author in the quality 
review. 
 
Rating Quality of individual studies 
The quality of each included study was rated as high, moderate or low using the QUADAS tool 
(12). Only studies of high or moderate quality were considered good enough for grading of 
scientific evidence and conclusions. 
 
Data synthesis 
All statistical analyses were conducted using the metandi and midas commands in Stata 13 
(StataCorp, College Station, Texas). A bivariate random-effects model was used to estimate 
average sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-) and 
diagnostic odds ratios (DOR), with 95% confidence intervals (CI). We also constructed the 
summary receiver operating characteristics (SROC) curve and the corresponding area under the 
curve (AUC) to summarize overall test performance (13).  
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We used coupled forest plots and measures of variability (variances and covariance of 
sensitivity and specificity across studies) to assess between-study heterogeneity (14, 15). We 
also undertook sensitivity analysis (excluding influential studies) to verify robustness of results. 
Finally, we assessed publication bias by plotting DOR against the effective sample size. With no 
bias, the plot should have an inverted symmetrical funnel shape. The degree of asymmetry was 
statistically assessed by regression of the logarithm of the DOR on the inverse of the square 
root of the effective sample size, weighted by effective sample size (16).  
 
Grading the scientific evidence across studies  
The quality of scientific evidence of the outcomes of PICO was rated according to the four 
GRADE levels (17). High (⊕⊕⊕⊕) - we are very confident that the true effect lies close to that of 
the estimate of the effect; Moderate ⊕⊕⊕Ο - we are moderately confident in the effect 
estimate; the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different; Low ⊕⊕ΟΟ - our confidence in the effect estimate 
is limited: the true effect may be substantially different from the estimate of the effect; Very 
Low ⊕ΟΟΟ - we have very little confidence in the effect estimate: the true effect is likely to 
be substantially different from the estimate of effect. 
The rated GRADE level is usually initially high, but confidence in the evidence may decrease 
stepwise during the analysis process for several reasons, including limitations in study design 
and/or quality, inconsistency or indirectness of results, imprecise estimates and probability of 
publication bias. Any disagreements on inclusion/exclusion criteria, rated quality of individual 
studies or quality of evidence of test methods were solved within the reviewer group by 
consensus. 
 
Results 
Selection of studies 
In this systematic review, 882 abstracts met the search criteria; 453 of them were excluded 
based on inclusion and exclusion criteria. This resulted in 429 published full-text articles that 
were assessed regarding inclusion and exclusion criteria. During this step, 376 articles were 
excluded (Supporting Information Table S1). The scientific quality of the articles meeting the 
inclusion and exclusion criteria was assessed using the QUADAS tool (12). Only studies with high 
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or moderate quality were considered suitable to use for grading the quality of scientific 
evidence. Twenty-two were assessed as low-quality and excluded from analysis (Supporting 
Information Table S2), leaving 31 articles (32 studies) for further analysis (Figure 1) (18-48). Two 
other studies (49, 50) were excluded since they reported on the same patients as in Jensen et al 
(29). 
 
Study characteristics 
The characteristics of the included studies are summarized in Supporting Information Tables S3-
5. Twenty-three studies were prospective cohort studies (21, 25-27, 31-48) and nine were case-
control-studies (18-20, 22-24, 28-30). The majority of sampling had occurred during the first 
trimester. Study designs varied and there were also variations in planning and execution, e.g. 
samples may have been frozen or not and results were reported back to patients in some 
studies. In the majority of studies results were not reported back to patients. Generally, the 
number of failed analyses and need for repeat sampling are not well reported. Six of the 32 
included studies did not report having a commercial partner (18, 25, 34, 39, 41, 51). 
The included studies were published from January 2011 to April 2, 2015. Nine studies were from 
centers offering NIPT for trisomies as part of a clinical service, with the results reported back to 
the patient (25, 26, 31, 39, 40, 42, 46-48). The remaining 23 used biobanked samples (18-24, 27-
30, 32-38, 41, 43-45). A reference test (inclusion criterion), either an invasive prenatal test or 
postnatal examination (phenotype), was used in all studies. 
Based on QUADAS and taking into account existence of commercial partner and study design, 
all of the included studies were assessed as being of moderate quality (risk of bias graph shown 
in Supporting Information Table S6). 
Five of the included studies were considered to investigate a general pregnant population (i.e. 
an average-risk population) (21, 33, 36, 37, 42). Two studies included both a high-risk and an 
average-risk population (40, 47). The remaining 25 studied a high-risk population. Thirteen of 
the 32 studies had a population exceeding 1,000 pregnancies (21, 26, 29, 31, 33, 35, 36, 38, 39, 
42, 46-48). 
In the case of the average-risk pregnant population, seven included studies reported on the 
performance of cfDNA analysis for T21, with a total of 156 TP T21 and 62,107 non-T21 TN 
singleton pregnancies (Table 1) (21, 33, 36, 37, 40, 42, 47). When it came to T18, there were a 
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total of 15 TP cases and 21,989 TN singleton pregnancies in the included six studies (21, 33, 36, 
37, 40, 42). As for T13, there were a total of six TP cases and 14,384 TN singleton pregnancies in 
the included five studies (Supporting Information Tables S7 and S8) (21, 36, 37, 40, 42). In the 
high-risk pregnant population, there were 1,839 TP T21 cases in total and the number of 
included singleton pregnancies exceeded 100,000 for all three trisomies (Table 1). 
The population in the study by Lau et al. (31) was classified as high-risk in our meta-analysis, 
since 46% of the women had an increased risk of carrying a fetus with a chromosome 
aberration; furthermore the median maternal age was 36. Dan et al. (26) report on 11,105 
clinical NIPT analyses, but sensitivity and specificity calculations were only based on the 3,000 
samples for which results of an invasive prenatal test were available. In this case, we decided to 
re-calculate sensitivity and specificity, in order to also include cases in which results of a 
postnatal clinical examination were available as a reference test. This made it possible to 
include 7,524 pregnancies in our meta-analysis. 
 
Meta-analyses 
A significant level of heterogeneity was observed, with greater variance in sensitivity than 
specificity for T21 and T13 in the high-risk population but greater variance in specifity than 
sensitivity for T18 in the high-risk population and T21 in the average risk population (Supporting 
Information Table S9). The corresponding prediction ellipses were not informative as most 
studies generated estimates in the upper left hand corner of the ROC plot.  
The meta-analyses for T21 in the high-risk population yield a pooled sensitivity of 0.998 (95% CI 
0.981 to 0.999) (Figure 2).  In the average-risk population, i.e. the general pregnant population, 
pooled sensitivity was 0.993 (95% 0.955 to 0.999) (Figure 3). In the case of T18 in the high-risk 
population, pooled sensitivity was 0.977 (95% CI 0.958 to 0.987) (Figure 4) and the 
corresponding figure for T13 was 0.975 (95% CI 0.819 to 0.997) (Figure 5). Sensitivity and 
specificity for T18 and T13 could not be calculated in the average-risk population due to the low 
number of studies (Figure 6). For trisomies 21, 18, and 13 in the high-risk population, and for 
T21 in the average-risk population, pooled specificity was 0.999 (95% 0.998 to 0.999) (Figures 2-
5). Individual studies clustered in the upper left-hand corner of their corresponding SROC 
curves, with AUC values of 1 (95% CI: 0.99 to 1.00) for trisomies 21, 18 and 13 in the high-risk 
population and 0.99 (95% CI: 0.98 to 1.00) for T21 in the average-risk population. Other 
measures of diagnostic performance (LR+ and LR- and DOR) are reported in Supporting 
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Information Table S10. 
We found evidence of publication bias for T21 in the high-risk (p=0.001) and average-risk 
populations (p=0.018), as well as for T18 in the high-risk population (p=0.010). There was no 
evidence of publication bias for T13 in the high-risk population (p=0.085).  
 
GRADE 
GRADE was used to determine confidence in the pooled estimates of sensitivity and specificity. 
The quality of evidence was considered to be moderate for T21 and T18 in the high-risk 
population, as well as for T21 in the average-risk population. When it came to T13 in the high-
risk population, the quality of evidence was limited (Table 1). No meta-analysis or grading for 
T13 and T18 in the average-risk population was performed due to lack of data (Figure 6). 
 
False positive and false negative results 
In this systematic review, the proportion of FP ranged between 2.7 % (T21 in the high-risk 
population) and 30 % (T13 in the general population) (Supporting Information Table S7). The 
proportion of FN was generally very low, i.e. 0.01 % at most (Supporting Information Table S8). 
 
Discussion 
This systematic review and meta-analysis show a pooled sensitivity of 0.993 (95% 0.955 to 
0.999) and a pooled specificity of 0.999 (95% 0.998 to 0.999) for T21 detection with NIPT in the 
general pregnant population. Corresponding values for T13 and T18 could not be calculated due 
to the low number of studies as well as an insufficient number of trisomy cases, compared to 
non-trisomy cases, in the pool. The majority of studies on cfDNA analysis for aneuploidy 
detection have so far been performed in selected high-risk pregnant populations. The findings 
in this meta-analysis extend those of previous reviews by adding data from studies in general 
pregnant (average-risk) populations. Due to the recent publication of several additional studies, 
including two very large ones (36, 47), our study has enhanced power to estimate the 
performance of cfDNA analysis in a general pregnant population. Moreover, there is now 
additional data on NIPT performance in a high-risk population. Pooled sensitivities in the 
selected high-risk pregnant population were 0.998 (95% CI 0.981 to 0.999), 0.977 (95% CI 0.958 
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to 0.987) and 0.975 (95% CI 0.819 to 0.997) for T21, T18 and T13, respectively. The pooled 
specificity in the high-risk population for trisomies 21, 18, and 13 is 0.999 (95% 0.998 to 0.999) 
(Figures 2-5). In the case of T21, our meta-analysis covered a sample consisting of 169,675 
singleton pregnancies and 2,004 trisomy cases, including an average-risk sample of 62,201 with 
157 T21 cases, about eight times as many pregnant women and twice as many trisomy cases as 
in a recent review on this topic by Gil et al. (8). The review by Gil et al, with a total of 1,051 T21 
cases and 21,608 unaffected fetuses, showed weighted pooled detection rates of 99.2% for T21, 
96.3% for T18 and 91.0% for T13 (8). 
The aim of applying GRADE is to ascertain how much confidence can be placed in a particular 
estimate of effect, whether the result will be sustainable and whether it is likely that new 
research will change the evidence. There is moderate quality of evidence, according to GRADE, 
underlying the pooled sensitivity of 0.993 and the pooled specificity of 0.999 for T21 detection 
in the general pregnant population, i.e. this result is likely to be close to the true effect. 
However, further improvement of cfDNA analysis may of course change these figures by 
enhancing method performance. GRADE assessment also demonstrates moderate quality of 
evidence for T21 and T18 detection in the high-risk pregnant population. Due to study quality 
and imprecision, the quality of evidence for T13 detection failed to reach the moderate level 
and was found to be low in the high-risk population. For T18 and T13, it was not possible to 
determine the quality of evidence in the general population due to insufficient data for these 
low-prevalence trisomies. Deeks’ symmetry test suggested the existence of publication bias in 
three of the four meta-analyses (T21 in the high-risk and average-risk populations, and T18 in 
the high-risk population but not for T13 in the high-risk population). The cfDNA technique was 
developed in a commercial setting with an early introduction to the clinical market. Only six of 
the 32 included studies did not report having a commercial partner (18, 25, 31, 34, 39, 41). The 
general impression is that commercial interests may affect results, and the meta-analysis by 
Taylor et al confirm the presence of publication bias (9). However we have nonetheless chosen 
not to degrade these findings according to the GRADE protocol.  
The two recently published meta-analyses that show separate data from a general pregnant 
population (average-risk) differ to ours in outcome (9, 10). The pooled sensitivity in the general 
pregnant population is higher in our meta-analysis (0.993) compared to the systematic review 
by Taylor et al (0.959) (9). Our reviews differ in some aspects, e.g. inclusion and exclusion 
criteria where we choose to exclude studies judged to be at high risk of bias (low quality 
studies) from the meta-analysis using QUADAS. In addition, we do not report pooled sensitivity 
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for T13 and T18 detection in the general pregnant population due to the low number of studies 
and limited data. The main difference of our data compared to Mackie et al (10) is the huge 
discrepancy when it comes to the number of patients included in the two different sub-
populations high- and normal risk (Table 1). This might at least partly explain the different 
outcomes, where our meta-analysis shows a difference in sensitivity for high- compared to 
normal risk population (0.998 compared to 0.993), a difference that the meta-analysis by 
Mackie et al. do not show. In addition, our analysis shows a somewhat higher sensitivity for T21 
analysis in a high-risk population 0.998 compared to Mackie et al (0.994) (10).  
The majority of the included studies were not performed in a clinical context but were 
performed retrospectively, using frozen biobanked plasma samples, with results not reported 
back to the patient (18-20, 22-24, 27-30, 32-34, 37, 38, 41, 43-45). This might have affected test 
performance when applied clinically, e.g. the no-result rate may have been underestimated. 
However, several larger studies from a clinical setting have been published during 2014-2015 
and the number of included patients in clinical studies thus exceeds by far the number of 
patients in the biobank studies (25, 26, 31, 35, 36, 39, 40, 42, 46-48). This limits the risk of such 
clinical consequences. The percentages of samples not generating a report back to the referring 
doctor is one aspect of cfDNA’s clinical usefulness that is insufficiently reported in most of the 
studies. There can be numerous reasons for this, on different levels of the process at which 
sample analysis might be problematic:  a sample might not fulfill the pre-analytic quality criteria 
(e.g. inadequate blood volume, incorrect labeling of tubes and delay in arrival at the laboratory) 
or analytic quality criteria (e.g. low fetal fraction or assay failure). In the studies performed in a 
clinical-like setting, an additional sample was required in 0.9-4.6% of cases (21, 24, 26, 31, 35, 
36, 39, 42, 47, 48), in addition to the samples failing to meet the pre-analytical criteria. None of 
the studies included in this meta-analysis were analyzed by ”intention-to-diagnose”, which 
would have made it easier to interpret the findings from a clinical perspective. The NIPT assay 
used for trisomy detection is based on new sequence technology and three different 
approaches are in clinical use, i.e. massive parallel (shotgun) sequencing (MPSS), targeted 
massive parallel sequencing (t-MPS), and t-MPS with the use of single nucleotide 
polymorphisms (SNP), with the different respective pros and cons. The majority of the included 
studies used MPSS, followed by t-MPS and SNP-based analysis. In this review, we have not 
studied the approaches separately.  
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This is the first meta-analysis using GRADE that includes a sufficient sample size to permit the 
conclusion that NIPT performs well as a screen for fetal T21 in a general pregnant population. 
More data is needed concerning T18 and T13. As the data in this meta-analysis suggests nearly 
equally good test performance in the general population, the scenario of using cfDNA instead of 
FTS will be increasingly considered. This approach will have the advantage of detecting more 
aneuploid pregnancies, nearly eliminating false reassurance and significantly reducing the 
number of women requiring an invasive test for confirmation. The major limiting factor for this 
development is the cost of the NIPT assay, which is still at least double the cost of FTS. 
Moreover, although the FP rate is low compared to FTS, women should still be advised to 
confirm a positive NIPT result by invasive testing if termination of pregnancy is under 
consideration. 
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Table S1. Full-text articles excluded according to criteria (n=376). 
 
Table S2. Full-text articles where the quality was rated as low using the QUADAS tool (n=22). 
 
Table S3. Characteristics of included studies reporting on non-invasive prenatal testing (NIPT) for 
trisomy 21 using cell-free DNA. 
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Table S4. Characteristics of included studies reporting on non-invasive prenatal testing (NIPT) for 
trisomy 18 using cell-free DNA. 
 
Table S5. Characteristics of included studies reporting on non-invasive prenatal testing (NIPT) for 
trisomy 13 using cell-free DNA. 
 
Table S6. Methodological quality summary of included full-text articles (n=31) based on the 
questions from the QUADAS tool (no 1-14) and a complementary question on commersial 
sponsoring (no 15). 
 
Table S7. Proportion of false positives. 
 
Table S8. Proportion of false negatives. 
 
Table S9. Levels of heterogeneity in studies. 
 
Table S10. Alternative measures of diagnostic accuracy (Positive and negative likelihood ratios [LR+ 
and LR-] and diagnostic odds ratio [DOR]) for trisomy 21 in high- and average-risk population, 
trisomy 18 in high-risk population and trisomy 13 in high-risk population. 
 
Legends of figures 
 
Figure 1. Flow chart summarizing selection of included studies. 
 
Figure 2. Meta-analysis of sensitivity and specificity of non-invasive prenatal testing (NIPT) for 
detecting trisomy 21 in a population at high risk of carrying a fetus with chromosome aberration. 
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Figure 3. Meta-analysis of sensitivity and specificity of non-invasive prenatal testing (NIPT) for 
detecting trisomy 21 in a population at average risk of carrying a fetus with chromosome aberration. 
 
Figure 4. Meta-analysis of sensitivity and specificity of non-invasive prenatal testing (NIPT) for 
detecting trisomy 18 in a population at high risk of carrying a fetus with chromosome aberration. 
 
Figure 5. Meta-analysis of sensitivity and specificity of non-invasive prenatal testing (NIPT) for 
detecting trisomy 13 in a population at high risk of carrying a fetus with chromosome aberration. 
 
Figure 6. Meta-analysis of sensitivity and specificity of non-invasive prenatal testing (NIPT) in a 
population at average risk of carrying a fetus with chromosome aberration: a) trisomy 18 b) trisomy 
13. 
 
Table 1. Summary of findings and quality of evidence (GRADE). 
 
Trisomy Population 
Probability 
(“risk”) 
Sample size 
(no of 
studies)  
Sensitivity, 
Pooled 
estimates  
(95 % CI) 
Specificity,
Pooled 
estimates  
(95 % CI) 
Quality of 
evidence 
Rating items True positive* 
(TP) 
 
False positive** 
(FP) 
 
False negative*** 
(FN) 
 
True Negative 
(TN)**** 
T21 High  107 474 (26) 
 
0.998 
(0.981–0.999) 
0.999 
(0.999-0.999) 
(⊕⊕⊕Ο) -1 Study 
design/quality 
1839 TP 
52 FP 
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8 FN 
105 575 TN 
T21 Average 62 201 (6)  0.993 
(0.955–0.999) 
0.999 
(0.998–0.999) 
(⊕⊕⊕Ο) -1 Study 
design/quality 
 
156 TP 
37 FP 
1 FN 
62 107 TN 
T18 High  146 465 (22)  0.977 
(0.958–0.987) 
0.999 
(0.998–0.999) 
(⊕⊕⊕Ο) -1 Study 
design/quality 
566 TP 
70 FP 
15 FN 
146 129 TN 
T13 High  137 078 (18)  0.975  
(0.819–0.997) 
0.999 
(0.999–0.999) 
(⊕⊕ΟΟ) -1 Study 
design/quality 
-1 imprecision 
134 TP 
56 FP 
10 FN 
137 499 TN 
 
*TP= trisomy is verified; **FP= incorrectly classified as trisomy ***FN= trisomy is incorrectly classified as 
normal ****TN= absence of trisomy is verified. 
⊕⊕⊕Οmoderate quality of evidence, ⊕⊕ΟΟlimited quality of evidence 
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